Can PET help spare chemo in HER2-positive breast cancer?
MDSpire News
November 17, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

The phase 2 PHERGain trial evaluated PET- and pathologic response–guided chemotherapy omission in patients with stage I to IIIA operable HER2-positive breast cancer.
In the adaptive-treatment group, estimated 5-year invasive disease-free survival was 90% after a median follow-up of 5.6 years, and nearly one-third avoided chemotherapy.
Among 86 patients with an early FDG-PET response and pathologic complete response without chemotherapy, estimated 5-year invasive disease-free survival was 92%.
The trial was not designed to compare treatment strategies, so its results do not establish the equivalence of chemotherapy-sparing and standard treatment.
Exploratory ctDNA detection was associated with less favorable outcomes, but the authors said prospective validation is needed before ctDNA-guided treatment decisions enter routine practice.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: